trending Market Intelligence /marketintelligence/en/news-insights/trending/z8jukfgi_dfldqbwsyeeya2 content esgSubNav
In This List

Contraceptive makers shun hormones; inputs on boosting US biosimilar competition


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Contraceptive makers shun hormones; inputs on boosting US biosimilar competition

Here are the editors' top picks for the week ended Sept. 7.

Contraceptive developers eschew hormones in pursuit of new products for women

Sixty years after the FDA approved the hormonal contraceptive pill, companies are still struggling to develop and successfully market nonhormonal alternatives.

Drugmakers, public weigh in on efforts to boost US biosimilar competition

The head of the U.S. Food and Drug Administration is not satisfied with the pace at which the American market for biosimilars — lower-cost versions of biologic medicines — is growing and sought public input on how to change that situation.

Chi-Med's homegrown cancer drug approval shows China's 'world class' research

Hutchison China MediTech Ltd. is the first Chinese company to domestically discover and develop an approved drug for a common cancer indication, a "major step" for the rising Chinese biotech industry.

Massive opioid legislative package set for Senate vote

Senate Republicans and Democrats have reached a bipartisan deal on a massive package of over 70 bills intended to combat the U.S. opioid crisis and are expected to vote on the legislation.

Of Mice Not Men: New Alzheimer's, nicotine pathways; making blood type O

A liver drug could help brain cells protect themselves from Alzheimer's damage, researchers are looking into a drug that could reduce nicotine cravings, and scientists have developed a way to make universal donor blood.

Americans want pre-existing conditions protected; not confident on drug prices

A new poll showed American voters — Democrats, Republicans and Independents — want lawmakers to ensure protections remain in place to prevent insurers from discriminating against patients with pre-existing medical conditions.

Senate acts to ban drug cost 'gag clauses'; House health panel mulls legislation

Lawmakers on both sides of Capitol Hill took steps to ban so-called gag clauses, which prevent pharmacists from telling customers when they can pay less out-of-pocket for their prescription medicines by not using their insurance plans.

Hospital groups refile HHS lawsuit protesting drug discount rule changes

Three hospital organizations have refiled a lawsuit against the U.S. Department of Health and Human Services seeking to reverse a rule that would reduce discounts hospitals receive for the 340B drug pricing program.

Bayer CEO says 'nothing changed' with company strategy amid Monsanto legal woes

Bayer AG CEO Werner Baumann says the company's strategy remains unchanged as it integrates Monsanto Co. into its business even as legal woes continue to plague the newly acquired company.

Pfizer complains to FDA about J&J, Amgen comments on biosimilar products

Pfizer Inc. said the companies provided "false and misleading representations" of biosimilars in general and asks the administration for clearer guidelines.

Capitol Checkup: Medicare indication coverage; pre-existing conditions battle

The administration has yet to provide evidence to back up its claims that allowing Medicare Part D plans to limit coverage of a drug to only certain uses would expand beneficiaries' choices and lower their costs.

CMS finds $1B savings from Medicare provider group program in 2017

The agency has previously criticized the accountable care organization shared savings program for not providing enough value, but new data shows that the current model generated over $1 billion of savings in 2017.